EDX Medical receives support from high net worth, experienced healthcare investor

EDX Medical Group plc

EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has announced that the Company has received a strategic investment of £300,000 from a private investor via the placing of 2,727,272 new ordinary shares of 1p each in the Company at a price of 11p per share.

The investment in the Company at a premium of 22 % on the current market share price will be used to support the expansion of EDX Medical’s capabilities and operations.

The investor is a highly experienced healthcare investor based in Saudi Arabia and has been assisted in the Placing by Capital Plus Partners, London.

An application has been made for the Placing Shares to be admitted to trading on the AQSE Growth Market and admission is expected to become effective on October 25, 2024.

Professor Sir Chris Evans, OBE, founder of EDX Medical, commented: “We are delighted that another high net worth, experienced healthcare investor with a track record in successful medical ventures has chosen to support EDX Medical. This investor’s extensive network of healthcare contacts in the Gulf is also of considerable importance to the marketing of our new products in that region.”

Dr Mike Hudson, Chief Executive Officer of EDX Medical, commented: “This investment is another declaration of support in our strategy of developing and providing class-leading diagnostic solutions that will help health professionals achieve better outcomes for patients.”

Total Voting Rights

In accordance with the Financial Conduct Authority’s Disclosure and Transparency Rules, the Company hereby announces that following the Placing, it will have 350,084,848 Ordinary Shares in issue, each share carrying the right to one vote.

The above figure of 350, 084,848 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority’s Disclosure and Transparency Rules.

The directors of EDX Medical accept responsibility for the contents of this announcement.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

EDX Medical Group to launch highly accurate early detection test for testicular cancer

EDX Medical Group is set to launch TC100, a groundbreaking early detection test for testicular cancer in the UK, offering unparalleled accuracy for improved patient care.

EDX Medical Group raises £3.0 million to accelerate its prostate cancer ‘super test’

EDX Medical Group plc has secured £3 million by issuing 21.4 million new shares at 14p each, boosting its innovative prostate cancer diagnostic efforts.

EDX Medical Group signs master service agreement with The Royal Marsden

EDX Medical Group has secured a three-year master service agreement with The Royal Marsden NHS Foundation Trust to provide innovative diagnostic solutions for cancer care.

EDX Medical develops new ‘super test’ for prostate cancer

EDX Medical Group plc unveils a revolutionary AI-driven prostate cancer 'super test,' offering high accuracy and personalised treatment insights.

EDX Medical strengthens shareholder value by cancelling legacy warrants

EDX Medical Group (LON:EDX) cancels 5.37 million warrants, enhancing stability and reducing potential dilution for shareholders amidst robust growth.

EDX Medical receives support from high net worth, experienced healthcare investor

EDX Medical Group (AQSE:EDX) secures a £300,000 strategic investment from a Saudi healthcare investor to expand its digital diagnostic products.

Search

Search